Status:
COMPLETED
Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
Lead Sponsor:
AstraZeneca
Conditions:
Pain
Diabetic Neuropathy
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate if AZD2066 can relieve the pain arising from painful diabetic neuropathy compared to placebo.
Eligibility Criteria
Inclusion
- Provision of informed consent prior to any study specific procedures.
- Clinical diagnosis of painful diabetic neuropathy.
- non-fertile females
Exclusion
- Other pain that may confound assessment of neuropathic pain.
- Ongoing significant peripheral arterial diseases, skin ulcers, or amputation in the lower extremities.
- History of psychotic disorders among first degree relatives.
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2009
Estimated Enrollment :
127 Patients enrolled
Trial Details
Trial ID
NCT00857623
Start Date
February 1 2009
End Date
August 1 2009
Last Update
November 12 2012
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Reserach Site
Bella Vista, Arkansas, United States
2
Research Site
National City, California, United States
3
Research Site
Walnut Creek, California, United States
4
Research Site
Clearwater, Florida, United States